Role of programmed cell death receptor 1 signaling pathway in cancer immunotherapy / 基础医学与临床

Research in immunotherapy has achieved important progress in tumor treatment. Programmed cell death receptor 1(PD-1) is mainly expressed on the T lymphocyte surface and serves as an important immune regu-lator. The interactions of PD-1 and its ligand, PD-L1 are involved in tumor-induced immunosuppression. Some of the approved antibody preparations targeting PD-1/PD-L1 signaling showed significant clinical benefits.